Atrial Flutter
📧 Sign up to get email alerts when something new happens for Atrial Flutter.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-07-02FDA Approved: AMIODARONE HYDROCHLORIDE — Supplemental Application (Advagen Pharma Limited)
FDA approved a supplemental application for amiodarone hydrochloride by Advagen Pharma Limited. This action confirms regulatory clearance fo…
-
FDA approval · 2015-07-01FDA Approved: SOTALOL HYDROCHLORIDE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for sotalol hydrochloride from Apotex Corp., indicating approval of a generic sotalol product.
-
FDA approval · 2015-06-16FDA Approved: SOTYLIZE — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for SOTYLIZE (sotalol hydrochloride) from Azurity Pharmaceuticals.
-
FDA approval · 2015-05-19FDA Approved: AMIODARONE HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for Amiodarone Hydrochloride (generic) from Chartwell RX, LLC, confirming the generic product's stat…
-
CLINICAL_TRIALS trial_result · 2015-05-12Clinical Trial Update: Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia [Phase 4]
Phase 4 clinical trial assessing whether fish oils (omega-3 fatty acids) can prevent atrial mechanical stunning and remodeling due to atrial…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-04-29Clinical Trial Update: Atrial Fibrillation/Flutter Outcome Risk Determination
This clinical trial update reports outcomes from a Vanderbilt University study focused on determining risk in atrial fibrillation and atrial…
-
FDA approval · 2015-04-28FDA Approved: SOTALOL HYDROCHLORIDE — Supplemental Application (Oxford Pharmaceuticals, LLC)
The FDA approved a supplemental application for sotalol hydrochloride by Oxford Pharmaceuticals, LLC. Sotalol is used to treat certain heart…
-
FDA approval · 2015-04-06FDA Approved: DIGOXIN — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for Digoxin, submitted by Amneal Pharmaceuticals of New York LLC.
-
FDA label_change · 2015-03-23FDA Approved: CARDIZEM LA — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental labeling application for Cardizem LA (diltiazem hydrochloride extended-release tablets) from Bausch Health US LL…
-
FDA approval · 2015-03-02FDA Approved: SOTALOL HYDROCHLORIDE — Supplemental Application (AiPing Pharmaceutical, Inc.)
FDA approved AiPing Pharmaceutical, Inc.'s supplemental application for sotalol hydrochloride, confirming approval of a generic product's su…
-
FDA approval · 2015-02-23FDA Approved: DIGOXIN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Digoxin submitted by Hikma Pharmaceuticals USA Inc.
-
FDA approval · 2015-02-17FDA Approved: FLECAINIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for flecainide acetate from Hikma Pharmaceuticals USA Inc., expanding or authorizing changes to this…
-
FDA approval · 2015-01-26FDA Approved: BREVIBLOC — Supplemental Application (Baxter Healthcare Corporation)
The FDA approved a supplemental application for Brevibloc (esmolol hydrochloride) submitted by Baxter Healthcare Corporation.
-
CLINICAL_TRIALS trial_result · 2015-01-16Clinical Trial Update: Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects [Phase 3]
A Phase 3 study evaluated intravenous tedisamil for rapidly converting atrial fibrillation or atrial flutter to normal sinus rhythm in femal…
-
CLINICAL_TRIALS trial_result · 2015-01-16Clinical Trial Update: Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects [Phase 3]
Phase 3 trial update showing completion of a study evaluating intravenous tedisamil for rapidly converting atrial fibrillation or flutter to…
-
CLINICAL_TRIALS trial_result · 2015-01-16Clinical Trial Update: Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects [Phase 3]
This update reports the completion of a Phase 3 trial evaluating intravenous tedisamil for the rapid conversion of atrial fibrillation or at…
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy
A Bayer-sponsored retrospective registry provides baseline data on the outcome of left atrial (LA) or left atrial appendage (LAA) thrombus i…
-
FDA approval · 2014-12-21FDA Approved: AMIODARONE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for amiodarone hydrochloride submitted by Sun Pharmaceutical Industries, signifying a regulatory…
-
FDA approval · 2014-12-21FDA Approved: AMIODARONE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for amiodarone hydrochloride from Sun Pharmaceutical Industries, Inc., indicating regulatory approva…
-
CLINICAL_TRIALS trial_result · 2014-10-29Clinical Trial Update: INR Control and Atrial Fibrillation in Primary Care in Spain (PAULA)
The PAULA clinical trial in Spain has completed and investigates INR control in primary care for atrial fibrillation and flutter.
-
FDA approval · 2014-10-22FDA Approved: SOTYLIZE — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved SOTYLIZE (sotalol hydrochloride) through an Original NDA from Azurity Pharmaceuticals for antiarrhythmic use.
-
FDA approval · 2014-09-04FDA Approved: SOTALOL HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's supplemental application for sotalol hydrochloride (generic). This action confirms regulatory clearance related to the g…
-
FDA approval · 2014-07-03FDA Approved: DIGOXIN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for DIGOXIN from Hikma Pharmaceuticals USA Inc., resulting in changes to the approved product labeli…
-
CLINICAL_TRIALS trial_result · 2014-06-23Clinical Trial Update: Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk [Phase 4]
A Phase 4 study from Biotronik evaluated combining their home monitoring system with predefined anticoagulation to reduce stroke risk in pat…
-
FDA approval · 2014-06-09FDA Approved: CORVERT — Supplemental Application (Pharmacia & Upjohn Company LLC)
FDA approved a supplemental application for CORVERT (ibutilide fumarate) filed by Pharmacia & Upjohn Company LLC, signaling a regulatory upd…